Black Diamond Therapeutics Inc (BDTX) - Net Assets
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has net assets worth $104.30 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($132.92 Million) and total liabilities ($28.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BDTX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $104.30 Million |
| % of Total Assets | 78.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -42.72% |
| 10-Year Change | N/A |
| Growth Volatility | 28.41 |
Black Diamond Therapeutics Inc - Net Assets Trend (2017–2025)
This chart illustrates how Black Diamond Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Black Diamond Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Black Diamond Therapeutics Inc (2017–2025)
The table below shows the annual net assets of Black Diamond Therapeutics Inc from 2017 to 2025. For live valuation and market cap data, see Black Diamond Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $112.21 Million | +34.73% |
| 2024-12-31 | $83.28 Million | -28.66% |
| 2023-12-31 | $116.74 Million | +0.90% |
| 2022-12-31 | $115.69 Million | -40.94% |
| 2021-12-31 | $195.90 Million | -36.35% |
| 2020-12-31 | $307.76 Million | +752.62% |
| 2019-12-31 | $-47.16 Million | -203.42% |
| 2018-12-31 | $-15.54 Million | -132.84% |
| 2017-12-31 | $-6.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Black Diamond Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45795900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.01% |
| Other Comprehensive Income | $101.00K | 0.09% |
| Other Components | $576.84 Million | 514.07% |
| Total Equity | $112.21 Million | 100.00% |
Black Diamond Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Technical Olympic S.A
AT:OLYMP
|
$95.74 Million |
|
KP Tissue Inc
TO:KPT
|
$95.78 Million |
|
Rekor Systems Inc
NASDAQ:REKR
|
$95.80 Million |
|
Y-Optics Manufacture Co. Ltd
KQ:066430
|
$96.03 Million |
|
Wonik Corporation
KQ:032940
|
$95.68 Million |
|
NextEye Co. Ltd
KQ:137940
|
$95.65 Million |
|
Huddly AS
OL:HDLY
|
$95.65 Million |
|
Kimlun Corporation Bhd
KLSE:5171
|
$95.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Black Diamond Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 83,285,000 to 112,211,000, a change of 28,926,000 (34.7%).
- Net income of 22,367,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 77,000.
- Other factors increased equity by 6,482,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $22.37 Million | +19.93% |
| Other Comprehensive Income | $77.00K | +0.07% |
| Other Changes | $6.48 Million | +5.78% |
| Total Change | $- | 34.73% |
Book Value vs Market Value Analysis
This analysis compares Black Diamond Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.93 | $1.67 | x |
| 2018-12-31 | $-1.11 | $1.67 | x |
| 2019-12-31 | $-1.31 | $1.67 | x |
| 2020-12-31 | $9.35 | $1.67 | x |
| 2021-12-31 | $5.41 | $1.67 | x |
| 2022-12-31 | $3.19 | $1.67 | x |
| 2023-12-31 | $2.66 | $1.67 | x |
| 2024-12-31 | $1.51 | $1.67 | x |
| 2025-12-31 | $1.95 | $1.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Black Diamond Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.93%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.95%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.27x
- Recent ROE (19.93%) is above the historical average (-33.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.93 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.38 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.54 Million |
| 2020 | -21.85% | 0.00% | 0.00x | 1.07x | $-98.03 Million |
| 2021 | -64.11% | 0.00% | 0.00x | 1.26x | $-145.19 Million |
| 2022 | -78.80% | 0.00% | 0.00x | 1.35x | $-102.74 Million |
| 2023 | -70.62% | 0.00% | 0.00x | 1.36x | $-94.12 Million |
| 2024 | -83.66% | 0.00% | 0.00x | 1.47x | $-78.00 Million |
| 2025 | 19.93% | 31.95% | 0.49x | 1.27x | $11.15 Million |
Industry Comparison
This section compares Black Diamond Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Black Diamond Therapeutics Inc (BDTX) | $104.30 Million | 0.00% | 0.27x | $95.69 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more